Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This Phase 2 randomized controlled trial will study the safety, tolerability, and efficacy of
Hydroxychloroquine in qualified patients with Alport syndrome. The trial will be open-label,
randomized, controlled and will enroll up to 50 patients.